An interventional study of Transient Elastography in Alcoholic Liver Disease, Alcohol Use Disorder and Alcohol Abuse, sponsored by Zealand University Hospital. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2023-05-17.
Sponsored by Zealand University Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to evaluate the efficacy of screening for liver disease with liver stiffness measurement on abstinence or light consumption after 6 months in individuals who are receiving treatment for alcohol use disorder and without a history of liver disease. The investigators will conduct a randomized controlled trial with concealed allocation comparing A) an invitation to a liver stiffness measurement, blood sampling and leaflet on alcohol-related disease (intervention) with B) an invitation to blood sampling (control). The primary outcome is 'abstinence or light consumption' (≤ 10 units/week) throughout the last months, and assessed 6 months after randomization.
74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.
This study's planned enrollment of 408 is above the median of 90 across 44 interventional studies indexed under Liver Diseases, Alcoholic.
Browse Liver Diseases, Alcoholic studies →Zealand University Hospital is the lead sponsor of 237 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
An invitation to a liver stiffness measurement (Transient Elastography), to blood sampling and a leaflet on alcohol-related disease.
Diagnostic Test: Transient Elastography
An invitation to screening by blood sampling with Fib-4
One transient elastography 1-2 weeks after randomization
Also known as: Fibroscan, Liver stiffness measurement
Alcohol abstinence or light consumption (≤ 10 units/week) the last 30 days (yes/no) assessed 6 months since randomization
Assessed By telephone interview or health record
Time frame: Assessed 6 months after randomization
Heavy drinking days last 30 days
Assessed by telephone interview or health record
Time frame: Assessed 6 months after since randomization
Change in AUDIT-C score (yes or no) since randomization
AUDIT: the Alcohol Use Disorders Identification Test is a validated manual for use in primary care to identify persons with hazardous and harmful patterns of alcohol consumption
Time frame: 6 months after randomization
Improvement or no decrease in motivation to cut down on alcohol (yes or no)
Assessed by telephone interview via questionnaire
Time frame: 6 months after randomization
Improvement or no decrease in physical and mental health-related quality of life (SF-12) (yes or no), calculated as the difference between baseline and follow-up.
SF 12 (12-Item Short Form Survey) is a validated self-reported outcome measure assessing the impact of health on an individual's everyday life
Time frame: Assessed 6 months after randomization
Comparing abstinence or light consumption last 30 days between those in the intervention group with a screen negative result with those in the control group.
Light consumption \< 10 units/week
Time frame: Assessed 6 months after randomization
Comparing alcohol consumption amount between those with a positive fibroscan vs. those with a negative fibroscan
Time frame: Assessed 6 months after randomization
Improvement or no decrease in smoking (yes/no)
By logistic regression
Time frame: Assessed 6 months after randomization
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started May 2023 (actual). Primary completion is estimated for Nov 2026, 41 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.